KEM® identified the most responsive subgroup to the proinsuline-derived therapy. And CD4/GRB+(CD4, granzyme B+ T-cell) was associated with the dose and identified as a surrogate endpoint

Ariana and academic collaborators from the Gastro Glyco Explorer consortium identify a novel single marker for Microsatellite instability (MSI), a distinct molecular subtype of gastric cancer.

Ariana shows that patients receiving the VAL401 treatment have statistically significant improvement in Overall Survival compared to those receiving no treatment, as well as a measurable improvement on Quality of Life.